FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895793349> ?p ?o ?g. }

• W2895793349 endingPage "S180" @default.
• W2895793349 startingPage "S180" @default.
• W2895793349 abstract "Pancreatic cancer remains a leading cause of cancer-related death. Despite ongoing research efforts in this area, there has been little progress over the past three decades. The rates of local and distant recurrences following surgical resection highlight the need for improvement in both local and systemic therapies. The primary objective of this study was to evaluate the feasibility and acute toxicity of neoadjuvant gemcitabine/nab-paclitaxel and HIGRT in patients with potentially resectable pancreatic cancer. Secondarily, we evaluated the surgical and pathologic outcomes of these patients. Patients with newly diagnosed, previously untreated, non-metastatic pancreatic ductal adenocarcinoma with Karnofsky performance scores (KPS) of 70 or higher, who were planned for surgical resection were prospectively enrolled on this single arm study. Patients received 2 cycles of gemcitabine/nab-paclitaxel followed by 25 Gy in 5 fractions HIGRT. Following neoadjuvant therapy patients were restaged and surgical resection was performed approximately 3-6 weeks post therapy. Patients received adjuvant chemotherapy at the discretion of the treating medical oncologist. Twenty-five patients were prospectively enrolled from 2015 to 2017. The median patient age was 68 (range 38-81). Twenty-eight percent of patients were considered resectable and 72% were borderline resectable (NCCN criteria) prior to initiation of neoadjuvant treatment, with 28% of patients being clinically node positive. Twenty-four of the 25 patients were able to undergo the full complement of neoadjuvant chemotherapy and radiation. Ultimately, 17 patients (68%) proceeded to surgical resection with 93% undergoing an R0 resection. Histologic grading of tumor response was assessed on surgical specimens and demonstrated marked response in 1 patient (6%), minimal to moderate response in 8 patients (47%), and poor response in 6 patients (35%). The median % of viable tumor and % fibrosis in the surgical specimens were 35% and 65%, respectively. Two patients were noted to have grade 2 adverse surgical events (wound infection, wound dehiscence) and there were no high grade (CTCAE grades 3-5) adverse surgical events appreciated. Neoadjuvant chemotherapy with gemcitabine/nab-paclitaxel and HIGRT is well-tolerated in patients with resectable or borderline resectable pancreatic cancer, with high rates of R0 resection and acceptable rates of post-operative complications. Given robust patient accrual, the initial enrollment was expanded to 40 patients to increase statistical power and accrual is ongoing." @default.
• W2895793349 created "2018-10-26" @default.
• W2895793349 creator A5000347168 @default.
• W2895793349 creator A5017916544 @default.
• W2895793349 creator A5019376688 @default.
• W2895793349 creator A5019935261 @default.
• W2895793349 creator A5024542231 @default.
• W2895793349 creator A5029870390 @default.
• W2895793349 creator A5046729820 @default.
• W2895793349 creator A5056949000 @default.
• W2895793349 creator A5059865374 @default.
• W2895793349 creator A5070443593 @default.
• W2895793349 creator A5073130519 @default.
• W2895793349 creator A5080553084 @default.
• W2895793349 creator A5087376683 @default.
• W2895793349 date "2018-11-01" @default.
• W2895793349 modified "2023-09-23" @default.
• W2895793349 title "Surgical and Pathologic Outcomes in Patients on a Phase II Trial of Neoadjuvant Chemotherapy and Hypofractionated Image-Guided Intensity Modulated Radiation Therapy (HIGRT) in Resectable and Borderline Resectable Pancreatic Cancer" @default.
• W2895793349 doi "https://doi.org/10.1016/j.ijrobp.2018.07.056" @default.
• W2895793349 hasPublicationYear "2018" @default.
• W2895793349 type Work @default.
• W2895793349 sameAs 2895793349 @default.
• W2895793349 citedByCount "0" @default.
• W2895793349 crossrefType "journal-article" @default.
• W2895793349 hasAuthorship W2895793349A5000347168 @default.
• W2895793349 hasAuthorship W2895793349A5017916544 @default.
• W2895793349 hasAuthorship W2895793349A5019376688 @default.
• W2895793349 hasAuthorship W2895793349A5019935261 @default.
• W2895793349 hasAuthorship W2895793349A5024542231 @default.
• W2895793349 hasAuthorship W2895793349A5029870390 @default.
• W2895793349 hasAuthorship W2895793349A5046729820 @default.
• W2895793349 hasAuthorship W2895793349A5056949000 @default.
• W2895793349 hasAuthorship W2895793349A5059865374 @default.
• W2895793349 hasAuthorship W2895793349A5070443593 @default.
• W2895793349 hasAuthorship W2895793349A5073130519 @default.
• W2895793349 hasAuthorship W2895793349A5080553084 @default.
• W2895793349 hasAuthorship W2895793349A5087376683 @default.
• W2895793349 hasConcept C121608353 @default.
• W2895793349 hasConcept C126322002 @default.
• W2895793349 hasConcept C141071460 @default.
• W2895793349 hasConcept C143998085 @default.
• W2895793349 hasConcept C2776694085 @default.
• W2895793349 hasConcept C2778292576 @default.
• W2895793349 hasConcept C2780210213 @default.
• W2895793349 hasConcept C2780258809 @default.
• W2895793349 hasConcept C2781182431 @default.
• W2895793349 hasConcept C509974204 @default.
• W2895793349 hasConcept C530470458 @default.
• W2895793349 hasConcept C71924100 @default.
• W2895793349 hasConceptScore W2895793349C121608353 @default.
• W2895793349 hasConceptScore W2895793349C126322002 @default.
• W2895793349 hasConceptScore W2895793349C141071460 @default.
• W2895793349 hasConceptScore W2895793349C143998085 @default.
• W2895793349 hasConceptScore W2895793349C2776694085 @default.
• W2895793349 hasConceptScore W2895793349C2778292576 @default.
• W2895793349 hasConceptScore W2895793349C2780210213 @default.
• W2895793349 hasConceptScore W2895793349C2780258809 @default.
• W2895793349 hasConceptScore W2895793349C2781182431 @default.
• W2895793349 hasConceptScore W2895793349C509974204 @default.
• W2895793349 hasConceptScore W2895793349C530470458 @default.
• W2895793349 hasConceptScore W2895793349C71924100 @default.
• W2895793349 hasIssue "3" @default.
• W2895793349 hasLocation W28957933491 @default.
• W2895793349 hasOpenAccess W2895793349 @default.
• W2895793349 hasPrimaryLocation W28957933491 @default.
• W2895793349 hasRelatedWork W114644245 @default.
• W2895793349 hasRelatedWork W1255356622 @default.
• W2895793349 hasRelatedWork W2358701816 @default.
• W2895793349 hasRelatedWork W2367105124 @default.
• W2895793349 hasRelatedWork W2376347278 @default.
• W2895793349 hasRelatedWork W2390548009 @default.
• W2895793349 hasRelatedWork W3029364823 @default.
• W2895793349 hasRelatedWork W3089077900 @default.
• W2895793349 hasRelatedWork W3092055942 @default.
• W2895793349 hasRelatedWork W4254486378 @default.
• W2895793349 hasVolume "102" @default.
• W2895793349 isParatext "false" @default.
• W2895793349 isRetracted "false" @default.
• W2895793349 magId "2895793349" @default.
• W2895793349 workType "article" @default.